FAS agreed on the price of the drug "Remdesivir" from COVID-19

The Federal Antimonopoly Service agreed on the price of the CORONAVIRUS drug Remdesivir in the amount of 3,840 rubles. for packing. This was reported in the press service of the department in TELEGRAM.

“The service has agreed on a price for the second generic drug Remdesivir of the Russian company R-Pharm in the amount of 3,840 rubles. per package," the statement said.

The department noted that the drug is intended for inpatient treatment of patients with covid-19 . it is included in the list of drugs recommended by the Ministry of HEALTH.

In November 2020, the World Health Organization (WHO) recommended against the use of Remdesivir in hospitalized patients, regardless of the severity of the disease. “At present, there is no evidence that Remdesivir improves survival rates and other treatment outcomes for these patients,” the organization’s press service explained.

Prior to this, the WHO conducted the Solidarity study, which found that the use of Remdesivir had “little or no effect” on 28-day mortality and in-hospital course of COVID-19 among hospitalized patients.